You are leaving Medscape Education

Cancel Continue

CME & Education

Return to Activity

Return to Activity: Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies

CME/CE Test

Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies

In the open label extension of the REDWOOD-HCM trial of aficamten, the Kansas City Cardiomyopathy Questionnaire (KCCQ) compared baseline values with those collected at week 12 and week 24.

Which of the following did patients experience as early as week 12?

Symptoms remained unchanged as measured by their KCCQ scores

Substantial symptom improvements as measured by the change in their KCCQ scores

Worsening symptoms as measured by the change in their KCCQ scores
A patient with symptomatic obstructive HCM at NYHA class II has continued obstruction despite metoprolol therapy. Echocardiography reveals left ventricular ejection fraction of 60%.

Which is the best next step in managing this patient?

Consider cardiac myosin inhibitor therapy

Continue current management

Perform follow-up echocardiography in 1 month